Cidara Therapeutics, Inc.
CDTXNASDAQHealthcare
$221.38
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio—
52W High$221.42
52W Low$15.22
Cidara Therapeutics, Inc. (CDTX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CDTX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($169.83M) | ($22.93M) | ($33.58M) | ($42.47M) | ($72.11M) |
| Depreciation & Amort. | $0.23M | $0.12M | $0.14M | ($1.23M) | $0.23M |
| Stock-Based Comp. | $3.91M | $3.06M | $3.53M | $4.01M | $4.09M |
| Change in Working Capital | ($13.93M) | ($3.92M) | $0.45M | $14.44M | $13.36M |
| Net Cash from Operations | ($176.53M) | ($22.43M) | ($28.47M) | ($25.23M) | ($54.41M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.13M) | ($0.51M) | ($0.12M) | ($0.04M) | ($0.19M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($0.13M) | ($0.51M) | ($0.12M) | ($0.04M) | ($0.19M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($0.28M) | $0.00M | ($2.59M) | ($4.44M) | ($2.96M) |
| Net Cash from Financing | $337.06M | $25.98M | ($0.95M) | $44.60M | $37.28M |
| Free Cash Flow | |||||
| Free Cash Flow | ($176.66M) | ($22.94M) | ($28.59M) | ($25.27M) | ($54.60M) |
| FCF Margin %(computed) | — | -98.51% | -44.36% | -50.98% | -452.45% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Cidara Therapeutics, Inc. data
About Cidara Therapeutics, Inc. (CDTX) Cash Flow Statement
Cidara Therapeutics, Inc. generated operating cash flow of ($0.18B) and free cash flow of ($0.18B) for 2024 — a FCF margin of -13855.84%. Capital expenditure was ($0.00B).
Frequently asked questions
CDTX · 4 questionsCidara Therapeutics, Inc. generated free cash flow of ($0.18B) for 2024, down 670.2% year-over-year.
CDTX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10